Riskpilot← Back to searchSign inGet full accessErgo-Nova Sweden AB
ABActiveOrg 5567902365SundsvallWholesale of pharmaceutical and medical goods · NACE 4646Est. 20090 employees
Revenue 2024
SEK 21,4M
-15% vs 2023
EBITDA margin
-3.4%
-226% vs 2023
Equity ratio
27.8%
Financial strength
Net profit 2024
SEK 13K
-97% vs 2023
| Revenue | SEK 21,4M | -15% |
| EBITDA | SEK -718K | -226% |
| Net profit | SEK 13K | -97% |
| Total assets | SEK 15,6M | +1% |
| Equity | SEK 4,3M | +0% |
| Employees | 0 | — |
Legal name
Ergo-Nova Sweden AB
Org number
5567902365
Legal form
Aktiebolag
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
2 oktober 2009
Share capital
SEK 400 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Bolaget skall bedriva försäljning och uthyrning av massagestolar samt annan därmed förenlig verksamhet.
Address
Sundsvall
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 19 525 | 26 655 | 35 569 | 25 073 | 21 394 |
| Staff expenses | — | — | — | — | — |
| EBITDA | 1 678 | 2 456 | 2 828 | 571 | −718 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | — |
| EBIT | 1 678 | 2 456 | 2 828 | 571 | −718 |
| Net financials | −129 | −97 | −9 | −153 | −120 |
| Profit before tax | 1 163 | 1 910 | 2 290 | 529 | 243 |
| Tax | −251 | −398 | −477 | −124 | −230 |
| Net profit | 912 | 1 512 | 1 813 | 405 | 13 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 9 521 | 14 867 | 17 829 | 15 470 | 15 598 |
| Equity | 2 592 | 3 104 | 3 916 | 4 322 | 4 335 |
| Long-term debt | 0 | 595 | 587 | 615 | 1 187 |
| Short-term debt | 5 114 | 8 903 | 10 531 | 7 848 | 8 171 |
| Total debt | 5 114 | 9 498 | 11 118 | 8 463 | 9 358 |
EBITDA margin
-3.4%
This company
15.8%
Market median
-122% vs market
20202024
Equity ratio
27.8%
This company
38.2%
Market median
-27% vs market
20202024
Return on equity
0.3%
This company
18.4%
Market median
-98% vs market
20202024
Net profit margin
0.1%
This company
8.1%
Market median
-99% vs market
20202024
Asset turnover
1.37×
This company
1.12×
Market median
+22% vs market
20202024
Debt / equity
2.60×
This company
0.62×
Market median
-319% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
KM Audit | Audit | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Chairman | 2022 | |
| Board of Directors | 2022 | |
| Board of Directors | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Ergo-Nova Sweden AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Kim Martin Lavin | Audit | 0 companies |
| Bent Bonde Pedersen | Chairman | 0 companies |
| Jonas Fredrik Pettersson | Board of Directors | 0 companies |
| Jens Stenport Nørgaard | Board of Directors | 0 companies |